ALKEM NSE filing

Alkem Laboratories Receives GST Order from Uttarakhand Authority

The RealCase readLow impact Neutral

Alkem Laboratories received a GST order demanding ₹27.14 lakh with a penalty of ₹27.79 lakh. The company will contest the order, believing there is no material impact.

Why it matters

The company stated that there is no material impact on financial, operation or other activities.

The market read

The announcement conveys factual information about receiving a GST order and the company's intention to contest it. There's no indication of positive or negative sentiment.

* Alkem Laboratories received an order from the Assistant Commissioner, Central Goods & Service Tax Division, Dehradun, Uttarakhand, on 03 December 2025. * The order pertains to the period from F.Y. 2018-2019 to 2022-2023. * The order demands GST of ₹27,14,603 along with a penalty of ₹27,79,266 and applicable interest. * The demand order alleges excess availment of ITC. * Alkem Laboratories disagrees with the order and will contest it, including filing an appeal. * The company believes there is no material impact on financial, operation or other activities.

Filing to action

What to do with a filing like this

Alkem Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under litigation updates. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.

That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.

See the model portfolios
Primary source

A plain-language summary of a public exchange filing by Alkem Laboratories Limited. Read the original for the full detail.

View original filing